Nlt 95% Powder Losartan EP Impurity M, 230971-72-9
Product Details
- Product NameNlt 95% Powder Losartan EP Impurity M, 230971-72-9
- CAS No.230971-72-9
- MFC44H44Cl2N12O
- MW827.81
- AppearanceSolidWhite to Light Yellow
- Melting point 128-130°C
- storage temp. Refrigerator
Molecular Weight: 827.81
Grade Standard: Analytical Grade
Documents Available: COA,HPLC,MASS,HNMR,CNMR,TGA,IR,SER
Molecular Formula: C44H44Cl2N12O
Iupac Name: 2-Butyl-1-[[2'-[2-[[2-butyl-4-chloro-1-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1H-imidaz
Usage/Application: Analytical
Solubility: DMSO
CAS Number: 230971-72-9
Country of Origin: Made in India
Purity: NLT 95%
Pharmacopoeia: EP
Form: Powder
Company Profile Introduction
Recommended supplier
-
VIP1年
- SAMSON BIOSCIENCES
- 230971-72-9 (1-((2'-(2-((1-((2'-(2H-tetrazol-5-yl)biphenyl-4-yl)methyl)-2-butyl-4-chloro-1H-imidazol-5-yl)methyl)-2H-tetrazol-5-yl)biphenyl-4-yl)methyl)-2-butyl-4-chloro-1H-imidazol-5-yl)methanol 98%
- Inquiry
- 2026-02-13
-
VIP4年
- GLP Pharma Standards
- 230971-72-9 NLT 95%
- Inquiry
- 2026-02-03
-
VIP0年
- GLP Pharma Standards
- 230971-72-9 NLT 95%
- Inquiry
- 2026-02-03
-
VIP4年
- GLP Pharma Standards
- Losartan EP Impurity K/Losartan USP Related Compound C / Losartan Aldehyde 114798-36-6 NLT 95%
- Inquiry
- 2026-04-02
-
VIP0年
- GLP Pharma Standards
- Losartan EP Impurity K/Losartan USP Related Compound C / Losartan Aldehyde 114798-36-6 NLT 95%
- Inquiry
- 2026-04-02
-
VIP4年
- GLP Pharma Standards
- Losartan EP Impurity-H / N-Trityl Losartan NLT 95%
- Inquiry
- 2026-04-02
-
VIP0年
- GLP Pharma Standards
- Losartan EP Impurity-H / N-Trityl Losartan NLT 95%
- Inquiry
- 2026-04-02
-
VIP4年
- GLP Pharma Standards
- 124750-67-0 Losartan Potassium Related Compound A/Losartan Impurity 35 NLT 95%
- Inquiry
- 2026-04-02
-
VIP0年
- GLP Pharma Standards
- 124750-67-0 Losartan Potassium Related Compound A/Losartan Impurity 35 NLT 95%
- Inquiry
- 2026-04-02
Other Switzerland
- Address: FF-4, Limbani Complex, Nr. Gormoh Hotel, Iscon-Bopal Road, Ambli, Ahmedabad, India - 380058
INQUIRY